Harvard Apparatus Regenerative Technology Inc.
Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. Its lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. The company's pipeline includes organ-… Read more
Harvard Apparatus Regenerative Technology Inc. (HRGN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.943x
Based on the latest financial reports, Harvard Apparatus Regenerative Technology Inc. (HRGN) has a cash flow conversion efficiency ratio of -0.943x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.47 Million) by net assets ($1.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Harvard Apparatus Regenerative Technology Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Harvard Apparatus Regenerative Technology Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Harvard Apparatus Regenerative Technology Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Harvard Apparatus Regenerative Technology Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ENVIVA INC. DL -001
F:XV6
|
N/A |
|
GameSparcs Co Ltd
TWO:6542
|
-0.017x |
|
CU Medical Systems Inc
KQ:115480
|
0.055x |
|
Jembo Cable Company Tbk
JK:JECC
|
0.079x |
|
Roscan Gold Corp
OTCQB:RCGCF
|
0.172x |
|
Netgem S.A.
LSE:0N9W
|
0.075x |
|
Atende S.A.
WAR:ATD
|
-0.165x |
|
ICTS International N.V
OTCQB:ICTSF
|
N/A |
Annual Cash Flow Conversion Efficiency for Harvard Apparatus Regenerative Technology Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Harvard Apparatus Regenerative Technology Inc. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $3.22 Million | $-4.85 Million | -1.506x | +64.28% |
| 2023-12-31 | $1.65 Million | $-6.94 Million | -4.216x | +18.35% |
| 2022-12-31 | $989.00K | $-5.11 Million | -5.163x | -695.06% |
| 2021-12-31 | $-3.03 Million | $-2.63 Million | 0.868x | +124.15% |
| 2020-12-31 | $1.12 Million | $-4.04 Million | -3.592x | +35.44% |
| 2019-12-31 | $1.09 Million | $-6.06 Million | -5.564x | -- |